Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.8400 (-4.27%) ($7.8300 - $8.4800) on Mon. Dec. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.72% (three month average) | RSI | 52 | Latest Price | $7.8400(-4.27%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(59%) IBB(58%) ARKK(57%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.86% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-7%) TLT(-7%) IGOV(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.86% (StdDev 3.72%) | Hourly BBV | 0 () | Intraday Trend | -4.5% | | | |
|
5 Day Moving Average | $7.78(0.77%) | 10 Day Moving Average | $7.81(0.38%) | 20 Day Moving Average | $7.79(0.64%) | To recent high | -4.3% | To recent low | 53.7% | Market Cap | $993m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |